A Population Pharmacokinetic Analysis of Emicizumab in Patients with Acquired Hemophilia a Enrolled in a Phase III Study (AGEHA)

被引：0
|
作者：
Yoneyama, Koichiro [1 ]
Fukazawa-Shinotsuka, Mizuki [1 ]
Saito, Tomohisa [1 ]
机构：
[1] Chugai Pharmaceut Co Ltd, Tokyo, Japan
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-155934
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2740 / 2741
页数：2
相关论文
共 50 条
  • [11] An improved approach for confirmatory phase III population pharmacokinetic analysis
    Hu, Chuanpu
    Zhou, Honghui
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (07): : 812 - 822
  • [12] Efficacy and safety of prophylaxis with emicizumab in hemophilia A: A study of 13 patients
    Gomez, M. Angeles Ocana
    Machin, Alejandro Ferrer
    Cabrera, Martin Vera
    Tosco, Karen Ilenia Alvarez
    De Paz, Mario Rios
    Garcia, Dolores De Dios
    MEDICINA CLINICA, 2024, 162 (03): : 134 - 137
  • [13] Pooled Population Pharmacokinetic Analysis of Phase I, II and III Studies of Linifanib in Cancer Patients
    Ahmed Hamed Salem
    Denise Koenig
    Dawn Carlson
    Clinical Pharmacokinetics, 2014, 53 : 347 - 359
  • [14] Pooled Population Pharmacokinetic Analysis of Phase I, II and III Studies of Linifanib in Cancer Patients
    Salem, Ahmed Hamed
    Koenig, Denise
    Carlson, Dawn
    CLINICAL PHARMACOKINETICS, 2014, 53 (04) : 347 - 359
  • [15] Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
    Shima, Midori
    Hanabusa, Hideji
    Taki, Masashi
    Matsushita, Tadashi
    Sato, Tetsuji
    Fukutake, Katsuyuki
    Kasai, Ryu
    Yoneyama, Koichiro
    Yoshida, Hiroki
    Nogami, Keiji
    BLOOD ADVANCES, 2017, 1 (22) : 1891 - 1899
  • [16] Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation
    Pezeshkpoor, Behnaz
    Sereda, Nadja
    Becker-Gotot, Janine
    Berkemeier, Ann-Cristin
    Matuschek, Isabell
    Muller, Jens
    Urs, Samhitha Urs Ramaraje
    Singh, Sneha
    Klein, Claudia
    Marquardt, Natascha
    Oldenburg, Johannes
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2025, 23 (01) : 85 - 96
  • [17] Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically III Patients
    Heffernan, Aaron J.
    Sime, Fekade B.
    Kumta, Nilesh
    Wallis, Steven C.
    McWhinney, Brett
    Ungerer, Jacobus
    Wong, Gloria
    Joynt, Gavin M.
    Lipman, Jeffrey
    Roberts, Jason A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (06)
  • [18] AN ITALIAN PHARMACOUTILIZATION ANALYSIS IN PATIENTS WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS AFTER SWITCHING TO EMICIZUMAB
    Perrone, V
    Leogrande, M.
    Motta, L.
    Tempre, R.
    Bendinelli, S.
    Ferrario, M.
    Esposti, L. Degli
    VALUE IN HEALTH, 2024, 27 (12)
  • [19] A study of 65 patients with acquired hemophilia A in Taiwan
    Huang, Shang-Yi
    Tsay, Woei
    Lin, Shyuann-Yuh
    Hsu, Szu-Chun
    Hung, Mei-Hwa
    Shen, Ming-Ching
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2015, 114 (04) : 321 - 327
  • [20] Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada
    Yu, Jacky K. K.
    Wong, William W. L.
    Keepanasseril, Arun
    Iorio, Alfonso
    Edginton, Andrea N. N.
    HAEMOPHILIA, 2023, 29 (02) : 488 - 497
12345